June 15, 2009 - FluoroPharma Inc. will present phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET radiotracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.
The results of this study will be presented by David Elmaleh, M.D., director of contrast media chemistry at the Massachusetts General Hospital and associate professor at Harvard Medical School, at the "New Tracers, New Agents and New Stressors" scientific session 1:15-1:30 p.m. (EDT), Tuesday, June 16.
BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually.
FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries.
For more information: www.fluoropharma.com
July 30, 2024 
